ACADIA Pharmaceuticals, Inc.

NASDAQ: ACAD
$53.66
-$0.80 (-1.5%)
Closing price January 15, 2021
A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth...
Health care has been a top performer this year, and there is every reason to believe that performance will carry through into 2021. These are four of the highest-ranked health care ideas from the...
Monday's top analyst upgrades and downgrades included Bristol-Myers Squibb, Chewy, DraftKings, Exxon Mobil, McAfee, Nvidia, Square, Tilray and Walt Disney.
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
Tuesday's top analyst upgrades and downgrades included Albertsons, Alphabet, Carnival, Coeur Mining, Devon Energy, Halliburton, Skyworks Solutions, Tesla, Walt Disney and Zendesk.
These nine stocks made big moves, up or down, after the close on Monday, July 20, 2020.
Canaccord Genuity recently released a report detailing some of the biggest biotech catalysts coming out over these next six months.
Thursday's top analyst upgrades and downgrades included Bed Bath & Beyond, Ciena, DocuSign, eHealth, Faceboook, Netflix, PNC Financial Services, Square, Tilray, Twitter and Zoom Video Communications.
Monday's top analyst upgrades, downgrades and initiations included Adobe, Amgen, Bank of America, Broadcom, CME, Goldman Sachs, Micron Technology, PepsiCo, UnitedHealth, Urban Outfitters and Vertex...
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of December.
Acadia shares made a handy gain on Monday after the firm announced positive results from an eight-week Phase 2 study evaluating pimavanserin as a therapy for Parkinson’s disease patients with...
The top analyst upgrades, downgrades and initiations seen on Friday included Acadia Pharmaceuticals, Broadcom, CBOE Global Markets, Etsy, Gap, General Electric, Home Depot, Lowe's Companies, Oracle...
Acadia Pharmaceuticals shares rose sharply early Monday after the firm announced that its late-stage dementia study met its primary endpoint.
Acadia Pharmaceuticals shares dropped on Tuesday after the firm announced results from its late-stage study for the treatment of adult schizophrenia patients.